Division of Nephrology, Department of Medicine, Columbia University College of Physicians & Surgeons, New York, New York.
The Columbia University Renal Epidemiology (CURE) Group, New York, New York.
JAMA Intern Med. 2023 Nov 1;183(11):1238-1246. doi: 10.1001/jamainternmed.2023.5013.
Disparities in kidney transplant referral and waitlisting contribute to disparities in kidney disease outcomes. Whether these differences are rooted in population differences in comorbidity burden is unclear.
To examine whether disparities in kidney transplant waitlisting were present among a young, relatively healthy cohort of patients unlikely to have medical contraindications to kidney transplant.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used the US Renal Data System Registry to identify patients with end-stage kidney disease who initiated dialysis between January 1, 2005, and December 31, 2019. Patients who were older than 40 years, received a preemptive transplant, were preemptively waitlisted, or had documented medical comorbidities other than hypertension or smoking were excluded, yielding an analytic cohort of 52 902 patients. Data were analyzed between March 1, 2022, and February 1, 2023.
MAIN OUTCOME(S) AND MEASURE(S): Kidney transplant waitlisting after dialysis initiation.
Of 52 902 patients (mean [SD] age, 31 [5] years; 31 132 [59%] male; 3547 [7%] Asian/Pacific Islander, 20 782 [39%] Black/African American, and 28 006 [53%] White) included in the analysis, 15 840 (30%) were waitlisted for a kidney transplant within 1 year of dialysis initiation, 11 122 (21%) were waitlisted between 1 and 5 years after dialysis initiation, and 25 940 (49%) were not waitlisted by 5 years. Patients waitlisted within 1 year of dialysis initiation were more likely to be male, to be White, to be employed full time, and to have had predialysis nephrology care. There were large state-level differences in the proportion of patients waitlisted within 1 year (median, 33%; range, 15%-58%). In competing risk regression, female sex (adjusted subhazard ratio [SHR], 0.92; 95% CI, 0.90-0.94), Hispanic ethnicity (SHR, 0.77; 95% CI, 0.75-0.80), and Black race (SHR, 0.66; 95% CI, 0.64-0.68) were all associated with lower waitlisting after dialysis initiation. Unemployment (SHR, 0.47; 95% CI, 0.45-0.48) and part-time employment (SHR, 0.74; 95% CI, 0.70-0.77) were associated with lower waitlisting compared with full-time employment, and more than 1 year of predialysis nephrology care, compared with none, was associated with greater waitlisting (SHR, 1.51; 95% CI, 1.46-1.56).
This retrospective cohort study found that fewer than one-third of patients without major medical comorbidities were waitlisted for a kidney transplant within 1 year of dialysis initiation, with sociodemographic disparities in waitlisting even in this cohort of young, relatively healthy patients unlikely to have a medical contraindication to transplantation. Transplant policy changes are needed to increase transparency and address structural barriers to waitlist access.
肾脏移植推荐和等待名单中的差异导致了肾脏疾病结果的差异。这些差异是否源于合并症负担方面的人群差异尚不清楚。
检查在不太可能有肾脏移植医学禁忌症的年轻、相对健康的患者队列中,等待肾脏移植名单的差异是否存在。
设计、地点和参与者:这项回顾性队列研究使用了美国肾脏数据系统登记处,以确定在 2005 年 1 月 1 日至 2019 年 12 月 31 日期间开始透析的终末期肾病患者。排除年龄大于 40 岁、接受预先移植、预先等待移植或有记录的高血压或吸烟以外的医学合并症的患者,产生了一个分析队列,包含 52902 名患者。数据于 2022 年 3 月 1 日至 2023 年 2 月 1 日之间进行分析。
透析后等待肾脏移植。
在 52902 名患者(平均[标准差]年龄,31[5]岁;31132 名[59%]男性;3547 名[7%]亚洲/太平洋岛民,20782 名[39%]黑人/非裔美国人,28006 名[53%]白人)中,15840 名(30%)在透析开始后 1 年内等待肾脏移植,11122 名(21%)在透析开始后 1 至 5 年内等待,25940 名(49%)在 5 年内未等待。在透析开始后 1 年内等待移植的患者更可能是男性、白人、全职就业和接受过透析前肾脏护理。各州之间在 1 年内等待名单的患者比例存在较大差异(中位数,33%;范围,15%-58%)。在竞争风险回归中,女性(调整后的亚危险比[SHR],0.92;95%置信区间,0.90-0.94)、西班牙裔(SHR,0.77;95%置信区间,0.75-0.80)和黑人(SHR,0.66;95%置信区间,0.64-0.68)种族均与透析后等待名单的较低比例相关。失业(SHR,0.47;95%置信区间,0.45-0.48)和非全职就业(SHR,0.74;95%置信区间,0.70-0.77)与全职就业相比,等待名单的比例较低,与无透析前肾脏护理相比,超过 1 年的透析前肾脏护理与较高的等待名单(SHR,1.51;95%置信区间,1.46-1.56)相关。
这项回顾性队列研究发现,在透析开始后 1 年内,没有主要医学合并症的患者中,不到三分之一的患者等待肾脏移植,即使在这个年轻、相对健康的患者队列中,也存在等待名单方面的社会人口学差异,这些患者不太可能有肾脏移植的医学禁忌症。需要改变移植政策,以提高透明度,并解决等待名单准入方面的结构性障碍。